559327548	559327548	CD	B-NP	O
|	|	NN	I-NP	O
SMH	SMH	NN	I-NP	O
|	|	NN	I-NP	O
64379841	64379841	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
5528832	5528832	CD	B-NP	O
|	|	CC	I-NP	O
1/26/2007	1/26/2007	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Summary	Summary	NNP	I-NP	O
|	|	NNP	I-NP	O
Signed	Signed	NNP	I-NP	O
|	|	NNP	I-NP	O
DIS	DIS	NNP	I-NP	O
|	|	NNP	I-NP	O
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
6/11/2007	6/11/2007	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Signed	Signed	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
1/26/2007	1/26/2007	CD	B-NP	O
ATTENDING	ATTENDING	NN	I-NP	O
:	:	:	O	O
CAGEY	CAGEY	NNP	B-NP	O
,	,	,	O	O
COY	COY	NNP	B-NP	O
MD	MD	NNP	I-NP	O
SERVICE	SERVICE	NNP	I-NP	O
:	:	:	O	O
Cardiology	Cardiology	NNP	B-NP	O
.	.	.	O	O

PRINCIPAL	PRINCIPAL	JJ	B-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
:	:	:	O	O
Coronary	Coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

LIST	LIST	NN	B-NP	O
OF	OF	IN	B-PP	O
PROBLEMS	PROBLEMS	NNP	B-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

Coronary	Coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Status	Status	NNP	B-NP	O
post	post	IN	B-PP	O
MI	MI	NNP	B-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Diabetes	Diabetes	NN	B-NP	O
mellitus	mellitus	NN	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Hospital-acquired	Hospital-acquired	JJ	B-NP	O
pneumonia	pneumonia	NN	I-NP	O
.	.	.	O	O

HISTORY	HISTORY	NN	B-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
Mr.	Mr.	NNP	B-NP	O
Zaspel	Zaspel	NNP	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
75-year-old	75-year-old	JJ	I-NP	O
female	female	NN	I-NP	O
with	with	IN	B-PP	O
diabetes	diabetes	NN	B-NP	O
,	,	,	O	O
coronary	coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
CABG	CABG	NN	I-NP	O
in	in	IN	B-PP	O
1995	1995	CD	B-NP	O
,	,	,	O	O
recent	recent	JJ	B-NP	O
MIBI	MIBI	NN	I-NP	O
,	,	,	O	O
stress	stress	NN	B-NP	O
test	test	NN	I-NP	O
in	in	IN	B-PP	O
July	July	NNP	B-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
small	small	JJ	I-NP	O
area	area	NN	I-NP	O
of	of	IN	B-PP	O
reversible	reversible	JJ	B-NP	O
ischemia	ischemia	NN	I-NP	O
inferiorly	inferiorly	RB	B-ADVP	O
who	who	WP	B-NP	O
had	have	VBD	B-VP	O
peripheral	peripheral	JJ	B-NP	O
vascular	vascular	JJ	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
right	right	JJ	B-NP	O
CVA	CVA	NN	I-NP	O
status	status	NN	I-NP	O
post	post	NN	I-NP	O
IVC	IVC	NN	I-NP	O
filter	filter	NN	I-NP	O
for	for	IN	B-PP	O
DVT	DVT	NN	B-NP	O
,	,	,	O	O
triple	triple	JJ	B-NP	O
AAA	AAA	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
repair	repair	NN	I-NP	O
,	,	,	O	O
COPD	COPD	NN	B-NP	O
,	,	,	O	O
who	who	WP	B-NP	O
presented	present	VBD	B-VP	O
to	to	TO	B-PP	O
One	One	CD	B-NP	O
Memorial	Memorial	NNP	I-NP	O
Hospital	Hospital	NNP	I-NP	O
with	with	IN	B-PP	O
nausea	nausea	NN	B-NP	O
of	of	IN	B-PP	O
unclear	unclear	JJ	B-NP	O
source	source	NN	I-NP	O
and	and	CC	O	O
deep	deep	JJ	B-NP	O
lateral	lateral	JJ	I-NP	O
T	T	NN	I-NP	O
wave	wave	NN	I-NP	O
inversions	inversion	NNS	I-NP	O
in	in	IN	B-PP	O
EKG	EKG	NN	B-NP	B-protein
leads	lead	VBZ	B-VP	O
V2-V6	V2-V6	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
has	have	VBZ	B-VP	O
noted	note	VBN	I-VP	O
intermittent	intermittent	JJ	B-NP	O
fevers	fever	NNS	I-NP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
to	to	TO	B-PP	O
102	102	CD	B-NP	O
and	and	CC	O	O
sent	send	VBD	B-VP	O
into	into	IN	B-PP	O
the	the	DT	B-NP	O
Camptown	Camptown	NNP	I-NP	O
On	On	NNP	I-NP	O
Memorial	Memorial	NNP	I-NP	O
Hospital	Hospital	NNP	I-NP	O
by	by	IN	B-PP	O
her	her	PRP$	B-NP	O
VNA	VNA	NN	I-NP	B-protein
.	.	.	O	O

Please	Please	VB	B-VP	O
see	see	VB	I-VP	O
discharge	discharge	NN	B-NP	O
summary	summary	NN	I-NP	O
from	from	IN	B-PP	O
Sheyfle	Sheyfle	NNP	B-NP	O
Hospital	Hospital	NNP	I-NP	O
for	for	IN	B-PP	O
more	more	JJR	B-NP	O
details	detail	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
at	at	IN	B-PP	O
that	that	DT	B-NP	O
time	time	NN	I-NP	O
on	on	IN	B-PP	O
treatment	treatment	NN	B-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
left	left	JJ	I-NP	O
foot	foot	NN	I-NP	O
diabetic	diabetic	JJ	I-NP	O
ulcer	ulcer	NN	I-NP	O
on	on	IN	B-PP	O
Augmentin	Augmentin	NNP	B-NP	O
.	.	.	O	O

Over	Over	IN	B-PP	O
the	the	DT	B-NP	O
last	last	JJ	I-NP	O
week	week	NN	I-NP	O
prior	prior	JJ	B-ADJP	O
to	to	TO	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
increasing	increase	VBG	I-VP	O
nausea	nausea	NN	B-NP	O
,	,	,	O	O
diarrhea	diarrhea	NN	B-NP	O
without	without	IN	B-PP	O
abdominal	abdominal	JJ	B-NP	O
pain	pain	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
did	do	VBD	B-VP	O
have	have	VB	I-VP	O
mild	mild	JJ	B-NP	O
fevers	fever	NNS	I-NP	O
and	and	CC	O	O
increased	increase	VBN	B-NP	O
cough	cough	NN	I-NP	O
though	though	IN	B-SBAR	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
chest	chest	NN	I-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
orthopnea	orthopnea	NN	B-NP	O
or	or	CC	O	O
urinary	urinary	JJ	B-NP	O
complaints	complaint	NNS	I-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
the	the	DT	B-NP	O
Cea	Cea	NNP	I-NP	O
Sto	Sto	NNP	I-NP	O
Valley	Valley	NNP	I-NP	O
Hospital	Hospital	NNP	I-NP	O
,	,	,	O	O
they	they	PRP	B-NP	O
noted	note	VBD	B-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
deep	deep	JJ	B-NP	O
T-wave	T-wave	NN	I-NP	O
inversions	inversion	NNS	I-NP	O
laterally	laterally	RB	B-ADVP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
ruled	rule	VBN	I-VP	O
out	out	RP	B-PRT	O
for	for	IN	B-PP	O
DCS	DCS	NN	B-NP	B-cell_type
by	by	IN	B-PP	O
cardiac	cardiac	JJ	B-NP	B-protein
enzymes	enzyme	NNS	I-NP	I-protein
.	.	.	O	O

They	They	PRP	B-NP	O
transferred	transfer	VBD	B-VP	O
her	her	PRP	B-NP	O
to	to	TO	B-PP	O
Burns	Burns	NNP	B-NP	O
Memorial	Memorial	NNP	I-NP	O
Health	Health	NNP	I-NP	O
Care	Care	NNP	I-NP	O
for	for	IN	B-PP	O
consideration	consideration	NN	B-NP	O
of	of	IN	B-PP	O
cardiac	cardiac	JJ	B-NP	O
catheterization	catheterization	NN	I-NP	O
.	.	.	O	O

PAST	PAST	NNP	B-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

Type	Type	NN	B-NP	O
II	II	CD	I-NP	O
diabetes	diabete	NNS	I-NP	O
complicated	complicate	VBN	B-VP	O
by	by	IN	B-PP	O
peripheral	peripheral	JJ	B-NP	O
neuropathy	neuropathy	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Coronary	Coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
status	status	NN	I-NP	O
post	post	NN	I-NP	O
CABG	CABG	NN	I-NP	O
in	in	IN	B-PP	O
1995	1995	CD	B-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Congestive	Congestive	JJ	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

COPD	COPD	NN	B-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Peripheral	Peripheral	JJ	B-NP	O
vascular	vascular	JJ	I-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Hypertension	Hypertension	NN	B-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Chronic	Chronic	JJ	B-NP	O
kidney	kidney	NN	I-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Abdominal	Abdominal	JJ	B-NP	O
aortic	aortic	JJ	I-NP	O
aneurysm	aneurysm	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
repair	repair	NN	I-NP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Carotid	Carotid	JJ	B-NP	O
disease	disease	NN	I-NP	O
status	status	NN	I-NP	O
post	post	NN	I-NP	O
right	right	JJ	I-NP	O
CEA	CEA	NN	I-NP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

DVT	DVT	NN	B-NP	O
status	status	NN	I-NP	O
post	post	NN	I-NP	O
IVC	IVC	NN	I-NP	O
filter	filter	NN	I-NP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

Diverticulitis	Diverticulitis	NN	B-NP	O
,	,	,	I-NP	O
status	status	NN	I-NP	O
post	post	NN	I-NP	O
sigmoid	sigmoid	JJ	I-NP	O
colectomy	colectomy	NN	I-NP	O
.	.	.	O	O

12	12	CD	B-NP	O
.	.	.	O	O

Gout	Gout	NNP	B-NP	O
.	.	.	O	O

13	13	CD	B-NP	O
.	.	.	O	O

Left	Left	JJ	B-NP	O
foot	foot	NN	I-NP	O
diabetic	diabetic	JJ	I-NP	O
ulcer	ulcer	NN	I-NP	O
,	,	,	O	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
multiple	multiple	JJ	B-NP	O
different	different	JJ	I-NP	O
antibiotic	antibiotic	JJ	I-NP	O
courses	course	NNS	I-NP	O
including	include	VBG	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
,	,	,	O	O
Flagyl	Flagyl	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
nasalide	nasalide	NN	B-NP	O
,	,	,	O	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
Augmentin	Augmentin	NNP	B-NP	O
.	.	.	O	O

MEDICATIONS	MEDICATIONS	NNS	B-NP	O
PRIOR	PRIOR	NN	I-NP	O
TO	TO	TO	B-VP	O
ADMISSION	ADMISSION	NN	I-VP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Augmentin	Augmentin	IN	B-PP	O
875	875	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
2	2	CD	I-NP	O
.	.	.	O	O

OxyContin	OxyContin	NN	B-NP	O
8	8	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
3	3	CD	I-NP	O
.	.	.	O	O

Tylenol	Tylenol	NN	B-NP	O
as	as	IN	B-PP	O
needed	need	VBN	B-VP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Tessalon	Tessalon	NN	B-NP	O
perles	perle	VBZ	B-VP	O
p.r.n.	p.r.n.	NN	B-NP	B-protein
5	5	CD	I-NP	I-protein
.	.	.	O	O

Ativan	Ativan	IN	B-PP	O
0.5	0.5	CD	B-NP	O
at	at	IN	B-PP	O
bedtime	bedtime	NN	B-NP	B-protein
p.r.n.	p.r.n.	NN	I-NP	I-protein
6	6	CD	I-NP	I-protein
.	.	.	O	O

Atrovent	Atrovent	JJ	B-NP	O
nebulizer	nebulizer	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
7	7	CD	I-NP	O
.	.	.	O	O

Lasix	Lasix	NN	B-NP	O
30	30	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Glipizide	Glipizide	NN	B-NP	O
2.5	2.5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Gabapentin	Gabapentin	NN	B-NP	O
300	300	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
10	10	CD	I-NP	O
.	.	.	O	O

Multivitamin	Multivitamin	NN	B-NP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

Atenolol	Atenolol	NN	B-NP	O
25	25	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

12	12	CD	B-NP	O
.	.	.	O	O

Allopurinol	Allopurinol	DT	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

13	13	CD	B-NP	O
.	.	.	O	O

Aspirin	Aspirin	NN	B-NP	O
81	81	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

14	14	CD	B-NP	O
.	.	.	O	O

Lipitor	Lipitor	NN	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

ALLERGY/ADVERSE	ALLERGY/ADVERSE	NN	B-NP	O
DRUG	DRUG	NN	I-NP	O
REACTIONS	REACTIONS	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Sulfa	Sulfa	NNP	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
allergic	allergic	JJ	I-NP	O
reaction	reaction	NN	I-NP	O
is	be	VBZ	B-VP	O
unclear	unclear	JJ	B-ADJP	O
,	,	,	O	O
although	although	IN	B-SBAR	O
it	it	PRP	B-NP	O
has	have	VBZ	B-VP	O
noted	note	VBN	I-VP	O
anaphylaxis	anaphylaxis	NN	B-NP	O
on	on	IN	B-PP	O
previous	previous	JJ	B-NP	O
discharge	discharge	NN	I-NP	O
summaries	summary	NNS	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Theophylline	Theophylline	NN	B-NP	O
causes	cause	VBZ	B-VP	O
tongue	tongue	NN	B-NP	O
swelling	swelling	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Quinine	Quinine	NN	B-NP	O
reaction	reaction	NN	I-NP	O
unclear	unclear	JJ	B-ADJP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Iodine/IV	Iodine/IV	NN	B-NP	O
contrast	contrast	NN	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
is	be	VBZ	B-VP	O
noted	note	VBN	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
medical	medical	JJ	I-NP	O
record	record	NN	I-NP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
does	do	VBZ	B-VP	O
not	not	RB	I-VP	O
remember	remember	VB	I-VP	O
having	have	VBG	I-VP	O
an	an	DT	B-NP	O
adverse	adverse	JJ	I-NP	O
reaction	reaction	NN	I-NP	O
or	or	CC	O	O
allergic	allergic	JJ	B-NP	O
reaction	reaction	NN	I-NP	O
to	to	TO	B-PP	O
IV	IV	CD	B-NP	O
contrast	contrast	NN	I-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Iron	Iron	NNP	B-NP	O
,	,	,	O	O
this	this	DT	B-NP	O
reaction	reaction	NN	I-NP	O
is	be	VBZ	B-VP	O
unknown	unknown	JJ	B-ADJP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Erythromycin	Erythromycin	NN	B-NP	O
,	,	,	O	O
again	again	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
does	do	VBZ	B-VP	O
not	not	RB	I-VP	O
remember	remember	VB	I-VP	O
any	any	DT	B-NP	O
reaction	reaction	NN	I-NP	O
,	,	,	O	O
but	but	CC	O	O
apparently	apparently	RB	B-VP	O
has	have	VBZ	I-VP	O
hives	hive	NNS	B-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Levofloxacin	Levofloxacin	NN	B-NP	O
,	,	,	O	O
unclear	unclear	JJ	B-ADJP	O
what	what	WP	B-NP	O
the	the	DT	B-NP	O
reaction	reaction	NN	I-NP	O
is	be	VBZ	B-VP	O
.	.	.	O	O

She	She	PRP	B-NP	O
has	have	VBZ	B-VP	O
tolerated	tolerate	VBN	I-VP	O
this	this	DT	B-NP	O
in	in	IN	B-PP	O
April	April	NNP	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
foot	foot	NN	I-NP	O
ulcer	ulcer	NN	I-NP	O
.	.	.	O	O

It	It	PRP	B-NP	O
is	be	VBZ	B-VP	O
not	not	RB	O	O
clear	clear	JJ	B-ADJP	O
if	if	IN	B-SBAR	O
this	this	DT	B-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
rash	rash	NN	I-NP	O
or	or	CC	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
thought	think	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
possibly	possibly	RB	I-VP	O
related	relate	VBN	I-VP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
fever	fever	NN	I-NP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
,	,	,	O	O
but	but	CC	O	O
it	it	PRP	B-NP	O
is	be	VBZ	B-VP	O
not	not	RB	O	O
clear	clear	JJ	B-ADJP	O
what	what	WP	B-NP	O
the	the	DT	B-NP	O
actual	actual	JJ	I-NP	O
reaction	reaction	NN	I-NP	O
is	be	VBZ	B-VP	O
.	.	.	O	O

SOCIAL	SOCIAL	JJ	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
an	an	DT	B-NP	O
80-pack-year	80-pack-year	JJ	I-NP	O
smoker	smoker	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
is	be	VBZ	B-VP	O
currently	currently	RB	B-ADVP	O
smoking	smoking	NN	B-NP	O
.	.	.	O	O

PHYSICAL	PHYSICAL	NN	B-NP	O
EXAM	EXAM	NN	I-NP	O
ON	ON	NN	I-NP	O
ADMISSION	ADMISSION	NN	I-NP	O
:	:	:	O	O
Her	Her	PRP$	B-NP	O
temperature	temperature	NN	I-NP	O
was	be	VBD	B-VP	O
99	99	CD	B-ADVP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
pulse	pulse	NN	I-NP	O
was	be	VBD	B-VP	O
98	98	CD	B-ADVP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
was	be	VBD	B-VP	O
105/55	105/55	CD	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
respiratory	respiratory	JJ	I-NP	O
rate	rate	NN	I-NP	O
was	be	VBD	B-VP	O
18	18	CD	B-NP	O
when	when	WRB	B-ADVP	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
saturating	saturate	VBG	I-VP	O
94	94	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
general	general	JJ	B-ADJP	O
,	,	,	O	O
she	she	PRP	B-NP	O
is	be	VBZ	B-VP	O
in	in	IN	B-PP	O
no	no	DT	B-NP	O
acute	acute	JJ	I-NP	O
distress	distress	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
HEENT	HEENT	NN	I-NP	O
exam	exam	NN	I-NP	O
was	be	VBD	B-VP	O
unremarkable	unremarkable	JJ	B-ADJP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
cardiac	cardiac	JJ	I-NP	O
exam	exam	NN	I-NP	O
was	be	VBD	B-VP	O
regular	regular	JJ	B-NP	O
rate	rate	NN	I-NP	O
and	and	CC	I-NP	O
rhythm	rhythm	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
2/6	2/6	CD	I-NP	O
systolic	systolic	JJ	I-NP	O
murmur	murmur	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
apex	apex	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
lung	lung	NN	I-NP	O
exam	exam	NN	I-NP	O
was	be	VBD	B-VP	O
notable	notable	JJ	B-ADJP	O
for	for	IN	B-PP	O
crackles	crackle	NNS	B-NP	O
most	most	RBS	B-ADJP	O
prominent	prominent	JJ	I-ADJP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
lower	low	JJR	I-NP	O
lobe	lobe	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
abdomen	abdoman	NNS	I-NP	O
was	be	VBD	B-VP	O
soft	soft	JJ	B-NP	O
,	,	,	I-NP	O
obese	obese	JJ	I-NP	O
,	,	,	I-NP	O
nontender	nontender	JJ	I-NP	O
and	and	CC	I-NP	O
nondistended	nondistended	JJ	I-NP	O
with	with	IN	B-PP	O
good	good	JJ	B-NP	O
bowel	bowel	NN	I-NP	O
sounds	sound	NNS	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
extremities	extremity	NNS	I-NP	O
were	be	VBD	B-VP	O
significant	significant	JJ	B-ADJP	O
for	for	IN	B-PP	O
erythema	erythema	NN	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
shin	shin	NN	I-NP	O
without	without	IN	B-PP	O
warmth	warmth	NN	B-NP	O
or	or	CC	I-NP	O
tenderness	tenderness	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
also	also	RB	B-ADVP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
small	small	JJ	I-NP	O
1.5	1.5	CD	I-NP	O
cm	cm	NN	I-NP	O
ulceration	ulceration	NN	I-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
bottom	bottom	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
left	left	JJ	I-NP	O
foot	foot	NN	I-NP	O
which	which	WDT	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
present	present	JJ	B-ADJP	O
for	for	IN	B-PP	O
sometime	sometime	RB	B-NP	O
although	although	IN	B-SBAR	O
she	she	PRP	B-NP	O
says	say	VBZ	B-VP	O
that	that	IN	B-SBAR	O
it	it	PRP	B-NP	O
looks	look	VBZ	B-VP	O
better	good	JJR	B-ADJP	O
than	than	IN	B-PP	O
at	at	IN	B-PP	O
first	first	RB	B-ADVP	O
.	.	.	O	O

There	There	EX	B-NP	O
was	be	VBD	B-VP	O
no	no	DT	B-NP	O
purulence	purulence	NN	I-NP	O
or	or	CC	O	O
purulent	purulent	JJ	B-NP	O
drainage	drainage	NN	I-NP	O
from	from	IN	B-PP	O
the	the	DT	B-NP	O
wound	wound	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
neurologic	neurologic	JJ	I-NP	O
exam	exam	NN	I-NP	O
was	be	VBD	B-VP	O
unremarkable	unremarkable	JJ	B-ADJP	O
.	.	.	O	O

LABORATORY	LABORATORY	NN	B-NP	O
DATA	DATA	NN	I-NP	O
ON	ON	NN	I-NP	O
ADMISSION	ADMISSION	NN	I-NP	O
:	:	:	O	O
Her	Her	PRP$	B-NP	O
labs	lab	NNS	I-NP	O
were	be	VBD	B-VP	O
notable	notable	JJ	B-ADJP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
creatinine	creatinine	NN	I-NP	O
of	of	IN	B-PP	O
1.6	1.6	CD	B-NP	O
,	,	,	O	O
a	a	DT	B-NP	O
white	white	JJ	I-NP	O
count	count	NN	I-NP	O
of	of	IN	B-PP	O
4.1	4.1	CD	B-NP	O
,	,	,	O	O
with	with	IN	B-PP	O
11	11	CD	B-NP	O
%	%	NN	I-NP	O
eosinophils	eosinophil	NNS	I-NP	B-cell_type
.	.	.	O	O

Her	Her	PRP$	B-NP	O
hematocrit	hematocrit	NN	I-NP	B-protein
was	be	VBD	B-VP	I-protein
31.6	31.6	CD	B-NP	I-protein
,	,	,	O	O
and	and	CC	O	O
her	her	PRP$	B-NP	B-protein
albumin	albumin	NN	I-NP	I-protein
was	be	VBD	B-VP	I-protein
3	3	CD	B-NP	I-protein
.	.	.	O	O

PROCEDURES	PROCEDURES	NNS	B-NP	O
:	:	:	O	O
Cardiac	Cardiac	JJ	B-NP	O
catheterization	catheterization	NN	I-NP	O
:	:	:	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
done	do	VBN	I-VP	O
by	by	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Eeds	Eeds	NNP	I-NP	O
.	.	.	O	O

FINDINGS	FINDINGS	NNS	B-NP	O
:	:	:	O	O
Showed	Show	VBD	B-VP	O
a	a	DT	B-NP	O
right	right	JJ	I-NP	O
dominant	dominant	JJ	I-NP	O
circulation	circulation	NN	I-NP	O
.	.	.	O	O

There	There	EX	B-NP	O
were	be	VBD	B-VP	O
no	no	DT	B-NP	O
significant	significant	JJ	I-NP	O
left	left	JJ	I-NP	O
main	main	JJ	I-NP	O
lesions	lesion	NNS	I-NP	O
identified	identify	VBN	B-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
LAD	LAD	NN	I-NP	B-protein
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
tubular	tubular	JJ	I-NP	O
90	90	CD	I-NP	O
%	%	NN	I-NP	O
lesion	lesion	NN	I-NP	O
and	and	CC	O	O
the	the	DT	B-NP	O
diagonal	diagonal	JJ	I-NP	O
I	I	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
proximal	proximal	JJ	I-NP	O
tubular	tubular	JJ	I-NP	O
60	60	CD	I-NP	O
%	%	NN	I-NP	O
lesion	lesion	NN	I-NP	O
,	,	,	O	O
there	there	EX	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	B-ADVP	O
a	a	DT	B-NP	O
diffuse	diffuse	JJ	I-NP	O
80	80	CD	I-NP	O
%	%	NN	I-NP	O
lesion	lesion	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
proximal	proximal	JJ	I-NP	O
circumflex	circumflex	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
RCA	RCA	NNP	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
proximal	proximal	JJ	I-NP	O
75	75	CD	I-NP	O
%	%	NN	I-NP	O
lesion	lesion	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
mid	mid	JJ	I-NP	O
diffuse	diffuse	NN	I-NP	O
60	60	CD	B-NP	O
%	%	NN	I-NP	O
lesion	lesion	NN	I-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
PLV	PLV	NN	I-NP	O
tubular	tubular	JJ	I-NP	O
70	70	CD	I-NP	O
%	%	NN	I-NP	O
lesion	lesion	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
coronary	coronary	JJ	I-NP	O
artery	artery	NN	I-NP	O
bypass	bypass	NN	I-NP	O
grafts	graft	NNS	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
patent	patent	NN	I-NP	O
LIMA	LIMA	NN	I-NP	O
to	to	TO	B-PP	O
LAD	LAD	NN	B-NP	O
graft	graft	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
SVG	SVG	NN	I-NP	O
to	to	TO	B-PP	O
marginal	marginal	JJ	B-NP	O
I	I	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
100	100	CD	I-NP	O
%	%	NN	I-NP	O
lesion	lesion	NN	I-NP	O
during	during	IN	B-PP	O
this	this	DT	B-NP	O
catheterization	catheterization	NN	I-NP	O
due	due	JJ	B-ADJP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
moderate	moderate	JJ	I-NP	O
amount	amount	NN	I-NP	O
of	of	IN	B-PP	O
contrast	contrast	NN	B-NP	O
and	and	CC	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
chronic	chronic	JJ	I-NP	O
kidney	kidney	NN	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
they	they	PRP	B-NP	O
treated	treat	VBD	B-VP	O
the	the	DT	B-NP	O
RCA	RCA	NN	I-NP	B-protein
and	and	CC	O	O
placed	place	VBD	B-VP	O
a	a	DT	B-NP	O
3	3	CD	I-NP	O
x	x	SYM	I-NP	O
24	24	CD	I-NP	O
mm	mm	NN	I-NP	O
Taxus	Taxus	NN	I-NP	O
stent	stent	JJ	I-NP	O
ECHOCARDIOGRAM	ECHOCARDIOGRAM	NN	I-NP	O
:	:	:	O	O
On	On	IN	B-PP	O
7/9/07	7/9/07	CD	B-NP	O
,	,	,	O	O
showed	show	VBD	B-VP	O
an	an	DT	B-NP	O
estimated	estimate	VBN	I-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
of	of	IN	B-PP	O
50	50	CD	B-NP	O
%	%	NN	I-NP	O
with	with	IN	B-PP	O
inferoseptal	inferoseptal	JJ	B-NP	O
and	and	CC	I-NP	O
inferior	inferior	JJ	I-NP	O
severe	severe	JJ	I-NP	O
hypokinesis	hypokinesis	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
RV	RV	NN	I-NP	O
was	be	VBD	B-VP	O
normal	normal	JJ	B-ADJP	O
.	.	.	O	O

There	There	EX	B-NP	O
was	be	VBD	B-VP	O
mild	mild	JJ	B-NP	O
aortic	aortic	JJ	I-NP	O
stenosis	stenosis	NN	I-NP	O
.	.	.	O	O

Mild-to-moderate	Mild-to-moderate	JJ	B-NP	O
aortic	aortic	JJ	I-NP	O
regurgitation	regurgitation	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
valve	valve	JJ	I-NP	O
area	area	NN	I-NP	O
was	be	VBD	B-VP	O
1.2	1.2	CD	B-NP	O
cm2	cm2	NN	I-NP	O
.	.	.	O	O

There	There	EX	B-NP	O
was	be	VBD	B-VP	O
mild	mild	JJ	B-NP	O
mitral	mitral	JJ	I-NP	O
regurgitation	regurgitation	NN	I-NP	O
.	.	.	O	O

There	There	EX	B-NP	O
is	be	VBZ	B-VP	O
trace	trace	NN	B-NP	O
tricuspid	tricuspid	JJ	I-NP	O
regurgitation	regurgitation	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
artery	artery	NN	I-NP	O
systolic	systolic	JJ	I-NP	O
pressure	pressure	NN	I-NP	O
of	of	IN	B-PP	O
36	36	CD	B-NP	O
mm	mm	NN	I-NP	O
plus	plus	CC	O	O
right	right	JJ	B-NP	O
atrial	atrial	JJ	I-NP	O
pressure	pressure	NN	I-NP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
BY	BY	NN	I-NP	O
PROBLEM	PROBLEM	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Cardiovascular	Cardiovascular	NNP	B-NP	O
:	:	:	O	O
a.	a.	NNP	B-NP	O
Ischemia	Ischemia	NNP	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
because	because	IN	B-SBAR	O
they	they	PRP	B-NP	O
had	have	VBD	B-VP	O
deep	deep	JJ	B-NP	O
T	T	NN	I-NP	O
wave	wave	NN	I-NP	O
inversions	inversion	NNS	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
lateral	lateral	JJ	I-NP	O
leads	lead	NNS	I-NP	O
and	and	CC	O	O
are	be	VBP	B-VP	O
still	still	RB	I-VP	O
concerning	concern	VBG	I-VP	O
for	for	IN	B-PP	O
anginal	anginal	JJ	B-NP	O
equivalence	equivalence	NN	I-NP	O
of	of	IN	B-PP	O
nausea	nausea	NN	B-NP	O
and	and	CC	I-NP	O
vomiting	vomiting	NN	I-NP	O
.	.	.	O	O

It	It	PRP	B-NP	O
was	be	VBD	B-VP	O
decided	decide	VBN	I-VP	O
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
that	that	IN	B-SBAR	O
an	an	DT	B-NP	O
echocardiogram	echocardiogram	NN	I-NP	O
would	would	MD	B-VP	O
be	be	VB	I-VP	O
performed	perform	VBN	I-VP	O
and	and	CC	O	O
if	if	IN	B-SBAR	O
there	there	EX	B-NP	O
was	be	VBD	B-VP	O
evidence	evidence	NN	B-NP	O
of	of	IN	B-PP	O
any	any	DT	B-NP	O
regional	regional	JJ	I-NP	O
wall	wall	NN	I-NP	O
motion	motion	NN	I-NP	O
abnormalities	abnormality	NNS	I-NP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
would	would	MD	B-VP	O
be	be	VB	I-VP	O
taken	take	VBN	I-VP	O
directly	directly	RB	B-ADVP	O
to	to	TO	B-PP	O
cath	cath	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
echocardiogram	echocardiogram	NN	I-NP	O
as	as	IN	B-SBAR	O
noted	note	VBN	B-VP	O
above	above	RB	B-ADVP	O
showed	show	VBD	B-VP	O
inferior	inferior	JJ	B-NP	O
hypokinesis	hypokinesis	NN	I-NP	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
coronary	coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
taken	take	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
cath	cath	NN	I-NP	O
lab	lab	NN	I-NP	O
on	on	IN	B-PP	O
9/5/07	9/5/07	CD	B-NP	O
and	and	CC	O	O
they	they	PRP	B-NP	O
show	show	VBP	B-VP	O
two	two	CD	B-NP	O
____	____	NN	I-NP	O
that	that	IN	B-SBAR	O
one	one	CD	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
bypass	bypass	NN	I-NP	O
grafts	graft	NNS	I-NP	O
was	be	VBD	B-VP	O
completely	completely	RB	I-VP	O
occluded	occlude	VBN	I-VP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
not	not	RB	I-VP	O
visualized	visualize	VBN	I-VP	O
.	.	.	O	O

They	They	PRP	B-NP	O
also	also	RB	B-ADVP	O
saw	see	VBD	B-VP	O
that	that	IN	B-SBAR	O
there	there	EX	B-NP	O
was	be	VBD	B-VP	O
a	a	DT	B-NP	O
proximal	proximal	JJ	I-NP	O
RCA	RCA	NN	I-NP	O
lesion	lesion	NN	I-NP	O
60	60	CD	B-NP	O
%	%	NN	I-NP	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
found	find	VBN	I-VP	O
to	to	TO	I-VP	O
account	account	VB	I-VP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
inferior	inferior	JJ	I-NP	O
hypokinesis	hypokinesis	NN	I-NP	O
given	give	VBN	B-PP	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
arm	arm	NN	I-NP	O
circulation	circulation	NN	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
was	be	VBD	B-VP	O
stented	stente	VBN	I-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
Taxus	Taxus	NN	I-NP	O
stent	stent	NN	I-NP	O
.	.	.	O	O

Because	Because	IN	B-PP	O
of	of	IN	I-PP	O
her	her	PRP$	B-NP	O
kidney	kidney	NN	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
decided	decide	VBN	I-VP	O
not	not	RB	O	O
to	to	TO	B-VP	O
pursue	pursue	VB	I-VP	O
the	the	DT	B-NP	O
80	80	CD	I-NP	O
%	%	NN	I-NP	O
left	leave	VBD	B-VP	O
circ	circ	NN	B-NP	O
lesion	lesion	NN	I-NP	O
and	and	CC	O	O
this	this	DT	B-NP	O
was	be	VBD	B-VP	O
deferred	defer	VBN	I-VP	O
until	until	IN	B-PP	O
later	later	JJ	B-NP	O
point	point	NN	I-NP	O
as	as	IN	B-SBAR	O
this	this	DT	B-NP	O
was	be	VBD	B-VP	O
not	not	RB	I-VP	O
thought	think	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
causing	cause	VBG	I-VP	O
any	any	DT	B-NP	O
problems	problem	NNS	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
post	post	JJ	I-NP	O
cath	cath	NN	I-NP	O
ECG	ECG	NN	I-NP	O
was	be	VBD	B-VP	O
unchanged	unchanged	JJ	B-ADJP	O
and	and	CC	O	O
continued	continue	VBD	B-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
the	the	DT	B-NP	O
deep	deep	JJ	I-NP	O
lateral	lateral	JJ	I-NP	O
T	T	NN	I-NP	O
wave	wave	NN	I-NP	O
inversions	inversion	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
complain	complain	VB	I-VP	O
of	of	IN	B-PP	O
any	any	DT	B-NP	O
chest	chest	NN	I-NP	O
pain	pain	NN	I-NP	O
or	or	CC	I-NP	O
nausea	nausea	NN	I-NP	O
and	and	CC	O	O
vomiting	vomit	VBG	B-VP	O
during	during	IN	B-PP	O
her	her	PRP$	B-NP	O
admission	admission	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
aspirin	aspirin	NN	B-NP	O
and	and	CC	I-NP	O
Plavix	Plavix	NN	I-NP	O
initially	initially	RB	B-ADVP	O
although	although	IN	B-SBAR	O
as	as	IN	B-SBAR	O
noted	note	VBN	B-VP	O
below	below	IN	B-PP	O
she	she	PRP	B-NP	O
did	do	VBD	B-VP	O
have	have	VB	I-VP	O
an	an	DT	B-NP	O
apparent	apparent	JJ	I-NP	O
allergy	allergy	NN	I-NP	O
to	to	TO	B-PP	O
Plavix	Plavix	NN	B-NP	O
and	and	CC	O	O
thus	thus	RB	B-ADVP	O
was	be	VBD	B-VP	O
switched	switch	VBN	I-VP	O
to	to	TO	B-PP	O
ticlopidine	ticlopidine	NN	B-NP	O
250	250	CD	I-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
instead	instead	RB	I-ADVP	O
of	of	IN	B-PP	O
Plavix	Plavix	NN	B-NP	O
for	for	IN	B-PP	O
anticoagulation	anticoagulation	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
continued	continue	VBN	I-VP	O
Lipitor	Lipitor	NN	B-NP	O
80	80	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
Lopressor	Lopressor	NNP	B-NP	O
25	25	CD	I-NP	O
mg	mg	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
.	.	.	O	O

After	After	IN	B-PP	O
her	her	PRP$	B-NP	O
cath	cath	NN	I-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
originally	originally	RB	I-VP	O
planned	plan	VBN	I-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
would	would	MD	B-VP	O
go	go	VB	I-VP	O
back	back	RB	B-ADVP	O
to	to	TO	B-PP	O
cath	cath	NN	B-NP	O
for	for	IN	B-PP	O
intervention	intervention	NN	B-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
circulation	circulation	NN	I-NP	O
lesion	lesion	NN	I-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
given	give	VBN	B-PP	O
her	her	PRP$	B-NP	O
other	other	JJ	I-NP	O
medical	medical	JJ	I-NP	O
problems	problem	NNS	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
relative	relative	JJ	I-NP	O
stability	stability	NN	I-NP	O
hemodynamically	hemodynamically	RB	B-ADVP	O
and	and	CC	I-ADVP	O
symptomatically	symptomatically	RB	I-ADVP	O
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
decided	decide	VBN	I-VP	O
that	that	IN	B-SBAR	O
they	they	PRP	B-NP	O
would	would	MD	B-VP	O
wait	wait	VB	I-VP	O
and	and	CC	I-VP	O
decide	decide	VB	I-VP	O
later	later	RB	B-ADVP	O
if	if	IN	B-SBAR	O
this	this	DT	B-NP	O
lesion	lesion	NN	I-NP	O
needed	need	VBN	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
corrected	correct	VBN	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
future	future	NN	I-NP	O
or	or	CC	O	O
not	not	RB	O	O
.	.	.	O	O

b.	b.	RB	B-ADVP	O
Pump	Pump	NNP	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
significant	significant	JJ	I-NP	O
issues	issue	NNS	I-NP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
here	here	RB	B-ADVP	O
.	.	.	O	O

She	She	PRP	B-NP	O
remained	remain	VBD	B-VP	O
in	in	IN	B-PP	O
a	a	DT	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
range	range	NN	I-NP	O
of	of	IN	B-PP	O
100-120	100-120	CD	B-NP	O
throughout	throughout	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
beta	beta	NN	I-NP	O
blocker	blocker	NN	I-NP	O
as	as	IN	B-SBAR	O
noted	note	VBN	B-VP	O
above	above	RB	B-ADVP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
at	at	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
this	this	DT	B-NP	O
was	be	VBD	B-VP	O
switched	switch	VBN	I-VP	O
back	back	RB	B-ADVP	O
to	to	TO	B-PP	O
atenolol	atenolol	NN	B-NP	O
as	as	IN	B-PP	O
her	her	PRP$	B-NP	O
home	home	NN	I-NP	O
medications	medication	NNS	I-NP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
refused	refuse	VBD	B-VP	O
to	to	TO	I-VP	O
change	change	VB	I-VP	O
medications	medication	NNS	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
said	say	VBD	B-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
would	would	MD	B-VP	O
not	not	RB	I-VP	O
be	be	VB	I-VP	O
able	able	JJ	B-ADJP	O
to	to	TO	B-VP	O
afford	afford	VB	I-VP	O
new	new	JJ	B-NP	O
prescription	prescription	NN	I-NP	O
.	.	.	O	O

We	We	PRP	B-NP	O
did	do	VBD	B-VP	O
increase	increase	VB	I-VP	O
her	her	PRP$	B-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
atenolol	atenolol	NN	B-NP	O
to	to	TO	B-PP	O
25	25	CD	B-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
from	from	IN	B-PP	O
25	25	CD	B-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
as	as	IN	B-PP	O
her	her	PRP$	B-NP	O
requirement	requirement	NN	I-NP	O
of	of	IN	B-PP	O
beta	beta	SYM	B-NP	O
blockade	blockade	NN	I-NP	O
seemed	seem	VBD	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
higher	high	JJR	B-ADJP	O
than	than	IN	B-PP	O
what	what	WP	B-NP	O
her	her	PRP$	B-NP	O
home	home	NN	I-NP	O
dose	dose	NN	I-NP	O
was	be	VBD	B-VP	O
.	.	.	O	O

Given	Give	VBN	B-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
concurrent	concurrent	JJ	I-NP	O
renal	renal	JJ	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
would	would	MD	B-VP	O
probably	probably	RB	I-VP	O
be	be	VB	I-VP	O
useful	useful	JJ	B-ADJP	O
for	for	IN	B-SBAR	O
her	her	PRP	B-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
on	on	IN	B-PP	O
an	an	DT	B-NP	O
ace	ace	NN	I-NP	O
inhibitor	inhibitor	NN	I-NP	O
ARB	ARB	NN	I-NP	B-protein
as	as	RB	B-ADVP	O
well	well	RB	I-ADVP	O
.	.	.	O	O

This	This	DT	B-NP	O
medication	medication	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
added	add	VBN	I-VP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
,	,	,	O	O
if	if	IN	B-SBAR	O
her	her	PRP$	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
tolerates	tolerate	VBZ	B-VP	O
it	it	PRP	B-NP	O
.	.	.	O	O

It	It	PRP	B-NP	O
was	be	VBD	B-VP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
lower	low	JJR	I-NP	O
side	side	NN	I-NP	O
here	here	RB	B-ADVP	O
,	,	,	O	O
so	so	IN	O	O
we	we	PRP	B-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
add	add	VB	I-VP	O
it	it	PRP	B-NP	O
.	.	.	O	O

We	We	PRP	B-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
diurese	diurese	VB	I-VP	O
her	her	PRP	B-NP	O
in	in	IN	B-PP	O
fact	fact	NN	B-NP	O
we	we	PRP	B-NP	O
held	hold	VBD	B-VP	O
her	her	PRP$	B-NP	O
Lasix	Lasix	NN	I-NP	O
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
because	because	IN	B-SBAR	O
she	she	PRP	B-NP	O
seemed	seem	VBD	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
volume	volume	NN	I-VP	O
depleted	deplete	VBN	I-VP	O
given	give	VBN	I-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
lot	lot	NN	I-NP	O
of	of	IN	B-PP	O
diarrhea	diarrhea	NN	B-NP	O
,	,	,	O	O
this	this	DT	B-NP	O
again	again	RB	B-ADVP	O
will	will	MD	B-VP	O
need	need	VB	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
reconsidered	reconsider	VBN	I-VP	O
if	if	IN	B-SBAR	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
increased	increase	VBN	I-VP	O
edema	edema	NN	B-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
can	can	MD	B-VP	O
be	be	VB	I-VP	O
restarted	restart	VBN	I-VP	O
.	.	.	O	O

C	C	NN	B-NP	O
:	:	:	O	O
Rhythm	Rhythm	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
kept	keep	VBN	I-VP	O
on	on	IN	B-PP	O
telemetry	telemetry	NN	B-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
there	there	EX	B-NP	O
were	be	VBD	B-VP	O
no	no	DT	B-NP	O
significant	significant	JJ	I-NP	O
episodes	episode	NNS	I-NP	O
of	of	IN	B-PP	O
arrhythmias	arrhythmia	NNS	B-NP	O
during	during	IN	B-PP	O
her	her	PRP$	B-NP	O
admission	admission	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

GI	GI	LS	B-LST	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
with	with	IN	B-PP	O
persistent	persistent	JJ	B-NP	O
nausea	nausea	NN	I-NP	O
and	and	CC	I-NP	O
diarrhea	diarrhea	NN	I-NP	O
from	from	IN	B-PP	O
Tlmamuthes	Tlmamuthes	NNP	B-NP	O
Medical	Medical	NNP	I-NP	O
Center	Center	NNP	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
diarrhea	diarrhea	NN	I-NP	O
resolved	resolve	VBD	B-VP	O
one	one	CD	B-NP	O
day	day	NN	I-NP	O
after	after	IN	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	B-cell_type
fecal	fecal	JJ	I-NP	I-cell_type
leukocytes	leukocyte	NNS	I-NP	I-cell_type
were	be	VBD	B-VP	O
positive	positive	JJ	B-ADJP	O
but	but	CC	O	O
her	her	PRP$	B-NP	O
C.	C.	NNP	I-NP	O
diff	diff	NN	I-NP	O
was	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
.	.	.	O	O

It	It	PRP	B-NP	O
was	be	VBD	B-VP	O
unclear	unclear	JJ	B-ADJP	O
what	what	WP	B-NP	O
the	the	DT	B-NP	O
etiology	etiology	NN	I-NP	O
of	of	IN	B-PP	O
this	this	DT	B-NP	O
diarrhea	diarrhea	NN	I-NP	O
was	be	VBD	B-VP	O
and	and	CC	O	O
we	we	PRP	B-NP	O
were	be	VBD	B-VP	O
going	go	VBG	I-VP	O
to	to	TO	I-VP	O
send	send	VB	I-VP	O
a	a	DT	B-NP	O
repeat	repeat	NN	I-NP	O
stool	stool	NN	I-NP	O
study	study	NN	I-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
she	she	PRP	B-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
have	have	VB	I-VP	O
any	any	DT	B-NP	O
diarrhea	diarrhea	NN	I-NP	O
afterwards	afterwards	RB	B-ADVP	O
and	and	CC	O	O
this	this	DT	B-NP	O
may	may	MD	B-VP	O
be	be	VB	I-VP	O
antibiotics	antibiotic	NNS	B-NP	O
associated	associate	VBN	B-VP	O
diarrhea	diarrhea	NN	B-NP	O
but	but	CC	O	O
it	it	PRP	B-NP	O
seemed	seem	VBD	B-VP	O
to	to	TO	I-VP	O
resolve	resolve	VB	I-VP	O
spontaneously	spontaneously	RB	B-ADVP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Pulmonary	Pulmonary	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
with	with	IN	B-PP	O
crackles	crackle	NNS	B-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
lower	low	JJR	I-NP	O
lobe	lobe	NN	I-NP	O
and	and	CC	O	O
some	some	DT	B-NP	O
wheezing	wheeze	VBG	I-NP	O
consistent	consistent	JJ	I-NP	O
with	with	IN	B-PP	O
COPD	COPD	NN	B-NP	O
and	and	CC	I-NP	O
pneumonia	pneumonia	NN	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
chest	ch	JJS	I-NP	O
x-ray	x-ray	NN	I-NP	B-DNA
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
showed	show	VBD	B-VP	O
a	a	DT	B-NP	O
right	right	RB	I-NP	O
lower	low	JJR	I-NP	O
lobe	lobe	NN	I-NP	O
infiltrate/atelectasis	infiltrate/atelectasis	NN	I-NP	O
.	.	.	O	O

We	We	PRP	B-NP	O
initially	initially	RB	B-ADVP	O
continued	continue	VBD	B-VP	O
her	her	PRP	B-NP	O
on	on	IN	B-PP	O
Augmentin	Augmentin	NNP	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
taking	take	VBG	I-VP	O
for	for	IN	B-PP	O
her	her	PRP$	B-NP	O
diabetic	diabetic	JJ	I-NP	O
foot	foot	NN	I-NP	O
ulcer	ulcer	NN	I-NP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
she	she	PRP	B-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
appear	appear	VB	I-VP	O
to	to	TO	I-VP	O
clinically	clinically	RB	I-VP	O
respond	respond	VB	I-VP	O
to	to	TO	B-PP	O
this	this	DT	B-NP	O
medication	medication	NN	I-NP	O
.	.	.	O	O

We	We	PRP	B-NP	O
held	hold	VBD	B-VP	O
her	her	PRP$	B-NP	O
antibiotics	antibiotic	NNS	I-NP	O
as	as	IN	B-SBAR	O
noted	note	VBN	B-VP	O
below	below	IN	B-PP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
ID	ID	NN	I-NP	O
section	section	NN	I-NP	O
and	and	CC	B-PP	O
after	after	IN	B-PP	O
that	that	DT	B-NP	O
her	her	PRP$	B-NP	O
white	white	JJ	I-NP	O
blood	blood	NN	I-NP	O
cell	cell	NN	I-NP	O
count	count	NN	I-NP	O
increased	increase	VBD	B-VP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
produced	produce	VBD	B-VP	O
some	some	DT	B-NP	O
purulent	purulent	JJ	I-NP	O
sputum	sputum	NN	I-NP	O
and	and	CC	O	O
Gram-negative	Gram-negative	JJ	B-NP	O
rods	rod	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
Gram-negative	Gram-negative	JJ	I-NP	O
rods	rod	NNS	I-NP	O
were	be	VBD	B-VP	O
later	later	RB	I-VP	O
speciated	speciate	VBN	I-VP	O
as	as	IN	B-PP	O
serratia	serratia	NN	B-NP	O
although	although	IN	B-SBAR	O
this	this	DT	B-NP	O
information	information	NN	I-NP	O
is	be	VBZ	B-VP	O
not	not	RB	O	O
available	available	JJ	B-ADJP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
discharge	discharge	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
hospital-acquired	hospital-acquired	JJ	I-NP	O
pneumonia	pneumonia	NN	I-NP	O
with	with	IN	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
and	and	CC	I-NP	O
ceftazidime	ceftazidime	NN	I-NP	O
to	to	TO	B-VP	O
complete	complete	VB	I-VP	O
a	a	DT	B-NP	O
14-day	14-day	JJ	I-NP	O
course	course	NN	I-NP	O
.	.	.	O	O

Clinically	Clinically	RB	B-ADVP	O
,	,	,	O	O
she	she	PRP	B-NP	O
appeared	appear	VBD	B-VP	O
to	to	TO	I-VP	O
improve	improve	VB	I-VP	O
on	on	IN	B-PP	O
this	this	DT	B-NP	O
regimen	regimen	NN	I-NP	O
,	,	,	O	O
although	although	IN	B-SBAR	O
her	her	PRP$	B-NP	O
white	white	JJ	I-NP	O
count	count	NN	I-NP	O
was	be	VBD	B-VP	O
still	still	RB	I-VP	O
elevated	elevate	VBN	I-VP	O
at	at	IN	B-PP	O
15	15	CD	B-NP	O
on	on	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
given	give	VBN	B-PP	O
her	her	PRP$	B-NP	O
overall	overall	JJ	I-NP	O
clinical	clinical	JJ	I-NP	O
stability	stability	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
lack	lack	NN	I-NP	O
of	of	IN	B-PP	O
fevers	fever	NNS	B-NP	O
and	and	CC	O	O
the	the	DT	B-NP	O
lack	lack	NN	I-NP	O
of	of	IN	B-PP	O
systemic	systemic	JJ	B-NP	O
symptoms	symptom	NNS	I-NP	O
.	.	.	O	O

We	We	PRP	B-NP	O
felt	feel	VBD	B-VP	O
comfortable	comfortable	JJ	B-ADJP	O
with	with	IN	B-PP	O
discharging	discharge	VBG	B-VP	O
her	her	PRP	B-NP	O
with	with	IN	B-PP	O
close	close	JJ	B-NP	O
follow	follow	VB	B-VP	O
up	up	IN	B-PRT	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Infectious	Infectious	JJ	B-NP	O
disease	disease	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
initially	initially	RB	I-VP	O
admitted	admit	VBN	I-VP	O
on	on	IN	B-PP	O
Augmentin	Augmentin	NNP	B-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
diabetic	diabetic	JJ	I-NP	O
foot	foot	NN	I-NP	O
ulcer	ulcer	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
notes	note	NNS	I-NP	O
from	from	IN	B-PP	O
Grantnas	Grantnas	NNP	B-NP	O
Healthcare	Healthcare	NNP	I-NP	O
by	by	IN	B-PP	O
the	the	DT	B-NP	O
Infectious	Infectious	NNP	I-NP	O
Disease	Disease	NNP	I-NP	O
Service	Service	NNP	I-NP	O
recommended	recommend	VBD	B-VP	O
a	a	DT	B-NP	O
2-4	2-4	CD	I-NP	O
week	week	NN	I-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
Augmentin	Augmentin	NNP	B-NP	O
for	for	IN	B-PP	O
her	her	PRP$	B-NP	O
diabetic	diabetic	JJ	I-NP	O
foot	foot	NN	I-NP	O
ulcer	ulcer	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
completed	complete	VBN	I-VP	O
three	three	CD	B-NP	O
weeks	week	NNS	I-NP	O
of	of	IN	B-PP	O
therapy	therapy	NN	B-NP	O
and	and	CC	O	O
thus	thus	RB	B-ADVP	O
we	we	PRP	B-NP	O
discontinued	discontinue	VBD	B-VP	O
this	this	DT	B-NP	O
medication	medication	NN	I-NP	O
as	as	IN	B-SBAR	O
it	it	PRP	B-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
seem	seem	VB	I-VP	O
that	that	IN	B-SBAR	O
there	there	EX	B-NP	O
was	be	VBD	B-VP	O
really	really	RB	B-ADVP	O
any	any	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
active	active	JJ	B-NP	O
infection	infection	NN	I-NP	O
in	in	IN	B-PP	O
her	her	PRP$	B-NP	O
foot	foot	NN	I-NP	O
.	.	.	O	O

After	After	IN	B-PP	O
holding	hold	VBG	B-VP	O
the	the	DT	B-NP	O
antibiotics	antibiotic	NNS	I-NP	O
for	for	IN	B-PP	O
three	three	CD	B-NP	O
days	day	NNS	I-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
white	white	JJ	I-NP	O
count	count	NN	I-NP	O
began	begin	VBD	B-VP	O
to	to	TO	I-VP	O
rise	rise	VB	I-VP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
developed	develop	VBD	B-VP	O
a	a	DT	B-NP	O
purulent	purulent	JJ	I-NP	O
cough	cough	NN	I-NP	O
as	as	IN	B-SBAR	O
noted	note	VBN	B-VP	O
above	above	RB	B-ADVP	O
,	,	,	O	O
this	this	DT	B-NP	O
was	be	VBD	B-VP	O
thought	think	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
a	a	DT	B-NP	O
hospital-acquired	hospital-acquired	JJ	I-NP	O
pneumonia	pneumonia	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
and	and	CC	I-NP	O
ceftazidime	ceftazidime	NN	I-NP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
will	will	MD	B-VP	O
complete	complete	VB	I-VP	O
a	a	DT	B-NP	O
14-day	14-day	JJ	I-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
these	these	DT	B-NP	O
antibiotics	antibiotic	NNS	I-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Endocrine	Endocrine	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
home	home	NN	B-ADVP	O
on	on	IN	B-PP	O
oral	oral	JJ	B-NP	O
hypoglycemics	hypoglycemic	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
switched	switch	VBN	I-VP	O
to	to	TO	I-VP	O
coverage	coverage	VB	I-VP	O
with	with	IN	B-PP	O
an	an	DT	B-NP	O
insulin	insulin	NN	I-NP	O
scale	scale	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
sugars	sugar	NNS	I-NP	O
were	be	VBD	B-VP	O
relatively	relatively	RB	I-VP	O
well	well	RB	I-VP	O
controlled	control	VBN	I-VP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
require	require	VB	I-VP	O
much	much	RB	B-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
way	way	NN	I-NP	O
of	of	IN	B-PP	O
supplemental	supplemental	JJ	B-NP	B-protein
insulin	insulin	NN	I-NP	I-protein
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Renal	Renal	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
chronic	chronic	JJ	B-NP	O
kidney	kidney	NN	I-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
baseline	baseline	NN	I-NP	O
creatinine	creatinine	NN	I-NP	O
was	be	VBD	B-VP	O
1.5-1	1.5-1	CD	B-NP	O
.6	.6	CD	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
and	and	CC	O	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
cath	cath	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
Mucomyst	Mucomyst	NN	B-NP	O
and	and	CC	O	O
bicarbonated	bicarbonate	VBN	B-NP	O
fluids	fluid	NNS	I-NP	O
for	for	IN	B-PP	O
renal	renal	JJ	B-NP	O
protection	protection	NN	I-NP	O
during	during	IN	B-PP	O
her	her	PRP$	B-NP	O
dilute	dilute	NN	I-NP	O
.	.	.	O	O

Because	Because	IN	B-PP	O
of	of	IN	I-PP	O
the	the	DT	B-NP	O
risk	risk	NN	I-NP	O
for	for	IN	B-PP	O
kidneys	kidney	NNS	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
cath	cath	NN	I-NP	O
was	be	VBD	B-VP	O
done	do	VBN	I-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
little	little	JJ	I-NP	O
amount	amount	NN	I-NP	O
of	of	IN	B-PP	O
dye	dye	NN	B-NP	O
as	as	IN	B-PP	O
possible	possible	JJ	B-ADJP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
creatinine	creatinine	NN	I-NP	O
remained	remain	VBD	B-VP	O
stable	stable	JJ	B-ADJP	O
throughout	throughout	IN	B-PP	O
her	her	PRP$	B-NP	O
admission	admission	NN	I-NP	O
and	and	CC	O	O
settled	settle	VBD	B-VP	O
out	out	RB	B-ADVP	O
at	at	IN	B-PP	O
1.6	1.6	CD	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
creatinine	creatinine	NN	I-NP	O
which	which	WDT	B-NP	O
is	be	VBZ	B-VP	O
the	the	DT	B-NP	O
baseline	baseline	NN	I-NP	O
.	.	.	O	O

ALLERGY	ALLERGY	NN	B-NP	O
:	:	:	O	O
During	During	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
admission	admission	NN	I-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
developed	develop	VBD	B-VP	O
a	a	DT	B-NP	O
rash	rash	NN	I-NP	O
on	on	IN	B-PP	O
4/15/06	4/15/06	CD	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
seen	see	VBN	I-VP	O
by	by	IN	B-PP	O
the	the	DT	B-NP	O
Allergy	Allergy	NNP	I-NP	O
and	and	CC	I-NP	O
Immunology	Immunology	NNP	I-NP	O
Service	Service	NNP	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
request	request	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
cath	cath	NN	I-NP	O
lab	lab	NN	I-NP	O
given	give	VBN	B-VP	O
that	that	IN	B-SBAR	O
there	there	EX	B-NP	O
was	be	VBD	B-VP	O
concern	concern	NN	B-NP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
this	this	DT	B-NP	O
rash	rash	NN	I-NP	O
because	because	IN	B-PP	O
of	of	IN	I-PP	O
her	her	PRP$	B-NP	O
Plavix	Plavix	NN	I-NP	O
.	.	.	O	O

They	They	PRP	B-NP	O
felt	feel	VBD	B-VP	O
that	that	IN	B-SBAR	O
this	this	DT	B-NP	O
was	be	VBD	B-VP	O
possible	possible	JJ	B-ADJP	O
.	.	.	O	O

This	This	DT	B-NP	O
was	be	VBD	B-VP	O
the	the	DT	B-NP	O
most	most	RBS	I-NP	O
likely	likely	JJ	I-NP	O
etiology	etiology	NN	I-NP	O
and	and	CC	B-PP	O
in	in	IN	B-PP	O
conjunction	conjunction	NN	B-NP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
high	high	JJ	I-NP	O
eosinophil	eosinophil	NN	I-NP	O
count	count	NN	I-NP	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
felt	feel	VBN	I-VP	O
that	that	IN	B-SBAR	O
this	this	DT	B-NP	O
was	be	VBD	B-VP	O
a	a	DT	B-NP	O
drug	drug	NN	I-NP	O
reaction	reaction	NN	I-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
Plavix	Plavix	NNP	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
switched	switch	VBN	I-VP	O
to	to	TO	B-PP	O
ticlopidine	ticlopidine	NN	B-NP	O
250	250	CD	I-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
rash	rash	NN	I-NP	O
appeared	appear	VBD	B-VP	O
to	to	TO	I-VP	O
improve	improve	VB	I-VP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
given	give	VBN	I-VP	O
claritin	claritin	NN	B-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
put	put	VBN	B-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
brief	brief	JJ	I-NP	O
prednisone	prednisone	NN	I-NP	O
taper	taper	NN	I-NP	O
given	give	VBN	B-VP	O
her	her	PRP$	B-NP	O
diffuse	diffuse	JJ	I-NP	O
rash	rash	NN	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
brisk	brisk	JJ	I-NP	O
eosinophilia	eosinophilia	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
should	should	MD	B-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
Allergy	Allergy	NNP	B-NP	O
and	and	CC	I-NP	O
Immunology	Immunology	NNP	I-NP	O
in	in	IN	B-PP	O
about	about	RB	B-NP	O
one	one	CD	I-NP	O
month	month	NN	I-NP	O
to	to	TO	B-VP	O
see	see	VB	I-VP	O
if	if	IN	B-SBAR	O
the	the	DT	B-NP	O
rash	rash	NN	I-NP	O
has	have	VBZ	B-VP	O
resolved	resolve	VBN	I-VP	O
and	and	CC	O	O
potentially	potentially	RB	B-VP	O
to	to	TO	I-VP	O
try	try	VB	I-VP	O
rechallenge	rechallenge	NN	B-NP	O
with	with	IN	B-PP	O
Plavix	Plavix	NN	B-NP	O
at	at	IN	B-PP	O
that	that	DT	B-NP	O
point	point	NN	I-NP	O
.	.	.	O	O

Cellulitis/diabetic	Cellulitis/diabetic	JJ	B-NP	O
foot	foot	NN	I-NP	O
ulcer	ulcer	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
had	have	VBN	I-VP	O
a	a	DT	B-NP	O
longstanding	longstanding	JJ	I-NP	O
diabetic	diabetic	JJ	I-NP	O
foot	foot	NN	I-NP	O
ulcer	ulcer	NN	I-NP	O
which	which	WDT	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
treated	treat	VBN	I-VP	O
by	by	IN	B-PP	O
wound	wound	NN	B-NP	O
care	care	NN	I-NP	O
VNA	VNA	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
at	at	IN	B-PP	O
Tha	Tha	NNP	B-NP	O
Hospital	Hospital	NNP	I-NP	O
.	.	.	O	O

We	We	PRP	B-NP	O
continued	continue	VBD	B-VP	O
the	the	DT	B-NP	O
Augmentin	Augmentin	NN	I-NP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
total	total	JJ	I-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
three	three	CD	B-NP	O
weeks	week	NNS	I-NP	O
and	and	CC	O	O
then	then	RB	B-VP	O
stopped	stop	VBD	I-VP	O
it	it	PRP	B-NP	O
.	.	.	O	O

We	We	PRP	B-NP	O
continued	continue	VBD	B-VP	O
her	her	PRP$	B-NP	O
dressing	dressing	NN	I-NP	O
changes	change	NNS	I-NP	O
and	and	CC	O	O
this	this	DT	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
followed	follow	VBN	I-VP	O
by	by	IN	B-PP	O
the	the	DT	B-NP	O
VNA	VNA	NN	I-NP	B-protein
at	at	IN	B-PP	O
home	home	NN	B-NP	O
.	.	.	O	O

There	There	EX	B-NP	O
was	be	VBD	B-VP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
active	active	JJ	B-NP	O
infection	infection	NN	I-NP	O
,	,	,	O	O
there	there	EX	B-NP	O
was	be	VBD	B-VP	O
no	no	DT	B-NP	O
purulence	purulence	NN	I-NP	O
or	or	CC	I-NP	O
erythema	erythema	NN	I-NP	O
around	around	IN	B-PP	O
the	the	DT	B-NP	O
area	area	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
ulcer	ulcer	NN	I-NP	O
and	and	CC	O	O
the	the	DT	B-NP	O
erythema	erythema	NN	I-NP	O
around	around	IN	B-PP	O
the	the	DT	B-NP	O
foot	foot	NN	I-NP	O
appeared	appear	VBD	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
stable	stable	JJ	B-ADJP	O
,	,	,	O	O
this	this	DT	B-NP	O
was	be	VBD	B-VP	O
most	most	RBS	B-NP	O
likely	likely	JJ	I-NP	O
chronic	chronic	JJ	I-NP	O
venous	venous	JJ	I-NP	O
stasis	stasis	NN	I-NP	O
change	change	NN	I-NP	O
and	and	CC	B-NP	O
not	not	RB	I-NP	O
a	a	DT	B-NP	O
true	true	JJ	I-NP	O
cellulitis	cellulitis	NN	I-NP	O
as	as	IN	B-SBAR	O
there	there	EX	B-NP	O
was	be	VBD	B-VP	O
no	no	DT	B-NP	O
warmth	warmth	NN	I-NP	O
or	or	CC	I-NP	O
tenderness	tenderness	NN	I-NP	O
in	in	IN	B-PP	O
this	this	DT	B-NP	O
region	region	NN	I-NP	O
.	.	.	O	O

CONSULTANTS	CONSULTANTS	NNS	B-NP	O
:	:	:	O	O
Allergy/Immunology	Allergy/Immunology	NNP	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
attending	attending	NN	I-NP	O
was	be	VBD	B-VP	O
Dr.	Dr.	NNP	B-NP	O
Frija	Frija	NNP	I-NP	O
.	.	.	O	O

PHYSICAL	PHYSICAL	NN	B-NP	O
EXAM	EXAM	NN	I-NP	O
AT	AT	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
afebrile	afebrile	JJ	B-ADJP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
pulse	pulse	NN	I-NP	O
was	be	VBD	B-VP	O
86	86	CD	B-ADVP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
was	be	VBD	B-VP	O
120/60	120/60	CD	B-ADVP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
respiratory	respiratory	JJ	I-NP	O
rate	rate	NN	I-NP	O
was	be	VBD	B-VP	O
20	20	CD	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
92-96	92-96	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
general	general	JJ	B-ADJP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
in	in	IN	B-PP	O
no	no	DT	B-NP	O
acute	acute	JJ	I-NP	O
distress	distress	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
JVP	JVP	NN	I-NP	B-protein
was	be	VBD	B-VP	O
about	about	IN	B-NP	O
7	7	CD	I-NP	O
cm	cm	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
small	small	JJ	B-NP	O
amount	amount	NN	I-NP	O
of	of	IN	B-PP	O
crackles	crackle	NNS	B-NP	O
at	at	IN	B-PP	O
bilateral	bilateral	JJ	B-NP	B-protein
bases	base	NNS	I-NP	I-protein
.	.	.	O	O

Her	Her	PRP$	B-NP	O
cardiac	cardiac	JJ	I-NP	O
exam	exam	NN	I-NP	O
was	be	VBD	B-VP	O
regular	regular	JJ	B-NP	O
rate	rate	NN	I-NP	O
and	and	CC	I-NP	O
rhythm	rhythm	NN	I-NP	O
with	with	IN	B-PP	O
normal	normal	JJ	B-NP	O
S1	S1	NN	I-NP	B-protein
and	and	CC	I-NP	O
S2	S2	NN	I-NP	B-protein
.	.	.	O	O

There	There	EX	B-NP	O
was	be	VBD	B-VP	O
a	a	DT	B-NP	O
2/6	2/6	CD	I-NP	O
systolic	systolic	JJ	I-NP	O
murmur	murmur	NN	I-NP	O
most	most	RBS	B-ADJP	O
prominent	prominent	JJ	I-ADJP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
lower	low	JJR	I-NP	O
sternal	sternal	JJ	I-NP	O
border	border	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
abdomen	abdomen	NN	I-NP	O
is	be	VBZ	B-VP	O
soft	soft	JJ	B-ADJP	O
,	,	,	O	O
nontender	nontender	JJ	B-ADJP	O
,	,	,	O	O
and	and	CC	O	O
nondistended	nondistended	JJ	B-ADJP	O
with	with	IN	B-PP	O
good	good	JJ	B-NP	O
bowel	bowel	NN	I-NP	O
sounds	sound	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	B-protein
had	have	VBD	B-VP	I-protein
1	1	CD	B-NP	I-protein
+	+	SYM	I-NP	O
edema	edema	NN	I-NP	O
bilaterally	bilaterally	RB	B-ADVP	O
with	with	IN	B-PP	O
small	small	JJ	B-NP	O
amounts	amount	NNS	I-NP	O
of	of	IN	B-PP	O
erythema	erythema	NN	B-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
distal	distal	JJ	I-NP	O
end	end	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
which	which	WDT	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
stable	stable	JJ	B-ADJP	O
.	.	.	O	O

There	There	EX	B-NP	O
is	be	VBZ	B-VP	O
no	no	DT	B-NP	O
associated	associate	VBN	I-NP	O
warmth	warmth	NN	I-NP	O
or	or	CC	I-NP	O
tenderness	tenderness	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
did	do	VBD	B-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
1.5	1.5	CD	I-NP	O
cm	cm	NN	I-NP	O
small	small	JJ	I-NP	O
ulcer	ulcer	NN	I-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
ventral	ventral	JJ	I-NP	O
aspect	aspect	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
left	left	JJ	I-NP	O
foot	foot	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
have	have	VB	I-VP	O
any	any	DT	B-NP	O
purulence	purulence	NN	I-NP	O
associated	associate	VBN	B-VP	O
with	with	IN	B-PP	O
it	it	PRP	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
neurologic	neurologic	JJ	I-NP	O
exam	exam	NN	I-NP	O
was	be	VBD	B-VP	O
nonfocal	nonfocal	JJ	B-ADJP	O
.	.	.	O	O

LABORATORY	LABORATORY	NN	B-NP	O
DATA	DATA	NN	I-NP	O
ON	ON	NN	I-NP	O
ADMISSION	ADMISSION	NN	I-NP	O
:	:	:	O	O
Notable	Notable	JJ	B-ADJP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
creatinine	creatinine	NN	I-NP	O
of	of	IN	B-PP	O
1.5	1.5	CD	B-NP	O
,	,	,	O	O
a	a	DT	B-NP	O
white	white	JJ	I-NP	O
blood	blood	NN	I-NP	O
cell	cell	NN	I-NP	O
count	count	NN	I-NP	O
of	of	IN	B-PP	O
15.89	15.89	CD	B-NP	O
,	,	,	O	O
with	with	IN	B-PP	O
82.7	82.7	CD	B-NP	O
%	%	NN	I-NP	O
neutrophils	neutrophil	NNS	I-NP	B-cell_type
,	,	,	O	O
3.8	3.8	CD	B-NP	O
%	%	NN	I-NP	O
eosinophils	eosinophil	NNS	I-NP	B-cell_type
.	.	.	O	O

Her	Her	PRP$	B-NP	O
hematocrit	hematocrit	NN	I-NP	O
was	be	VBD	B-VP	O
28.6	28.6	CD	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
baseline	baseline	NN	I-NP	O
appears	appear	VBZ	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
around	around	IN	B-PP	O
30	30	CD	B-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Ticlopidine	Ticlopidine	NN	B-NP	O
250	250	CD	I-NP	O
mg	mg	NN	I-NP	O
by	by	IN	B-PP	O
mouth	mouth	NN	B-NP	O
twice	twice	RB	B-NP	O
a	a	DT	I-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Atenolol	Atenolol	NN	B-NP	O
25	25	CD	I-NP	O
mg	mg	NN	I-NP	O
by	by	IN	B-PP	O
mouth	mouth	NN	B-NP	B-protein
b.i.d.	b.i.d.	NN	I-NP	I-protein
3	3	CD	I-NP	I-protein
.	.	.	O	O

Lipitor	Lipitor	NN	B-NP	O
80	80	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Prednisone	Prednisone	NN	B-NP	O
taper	taper	NN	I-NP	O
30	30	CD	I-NP	O
mg	mg	NN	I-NP	O
on	on	IN	B-PP	O
10/18/07	10/18/07	CD	B-NP	O
,	,	,	I-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
on	on	IN	B-PP	O
10/3/07	10/3/07	CD	B-NP	O
,	,	,	O	O
10	10	CD	B-NP	O
mg	mg	NN	I-NP	O
on	on	IN	B-PP	O
10/18/07	10/18/07	CD	B-NP	O
and	and	CC	O	O
then	then	RB	O	O
stop	stop	VB	B-VP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Vancomycin	Vancomycin	NN	B-NP	O
1	1	CD	I-NP	O
g	g	NN	I-NP	O
IV	IV	CD	B-NP	O
daily	daily	JJ	I-NP	O
,	,	,	I-NP	O
course	course	NN	I-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
completed	complete	VBN	I-VP	O
on	on	IN	B-PP	O
1/16/07	1/16/07	CD	B-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Ceftazidime	Ceftazidime	NN	B-NP	O
1	1	CD	I-NP	O
g	g	NN	I-NP	O
daily	daily	JJ	B-ADJP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
complete	complete	JJ	B-ADJP	O
on	on	IN	B-PP	O
1/16/07	1/16/07	CD	B-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Allopurinol	Allopurinol	DT	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Neurontin	Neurontin	NN	B-NP	O
300	300	CD	I-NP	O
mg	mg	NN	I-NP	O
three	three	CD	B-NP	O
times	time	NNS	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Tessalon	Tessalon	NN	B-NP	O
perles	perle	NNS	I-NP	O
as	as	IN	B-SBAR	O
needed	need	VBN	B-VP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

Ativan	Ativan	IN	B-PP	O
0.5	0.5	CD	B-NP	O
mg	mg	NN	I-NP	O
at	at	IN	B-PP	O
bedtime	bedtime	NN	B-NP	O
as	as	IN	B-SBAR	O
needed	need	VBN	B-VP	O
for	for	IN	B-PP	O
sleep	sleep	NN	B-NP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

Glipizide	Glipizide	NN	B-NP	O
2.5	2.5	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

12	12	CD	B-NP	O
.	.	.	O	O

DuoNeb	DuoNeb	IN	B-PP	O
every	every	DT	B-NP	O
4	4	CD	I-NP	O
hours	hour	NNS	I-NP	O
as	as	IN	B-SBAR	O
needed	need	VBN	B-VP	O
for	for	IN	B-PP	O
shortness	shortness	NN	B-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
.	.	.	O	O

13	13	CD	B-NP	O
.	.	.	O	O

Lasix	Lasix	NN	B-NP	O
30	30	CD	I-NP	O
mg	mg	NN	I-NP	O
by	by	IN	B-PP	O
mouth	mouth	NN	B-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

14	14	CD	B-NP	O
.	.	.	O	O

Aspirin	Aspirin	NN	B-NP	O
81	81	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

DISPOSITION	DISPOSITION	NN	B-NP	O
:	:	:	O	O
Home	Home	NN	B-NP	O
with	with	IN	B-PP	O
services	service	NNS	B-NP	O
.	.	.	O	O

PENDING	PENDING	VBG	B-VP	O
TESTS	TESTS	NNS	B-NP	O
:	:	:	O	O
As	As	IN	B-SBAR	O
noted	note	VBN	B-VP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
sputum	sputum	NN	I-NP	O
culture	culture	NN	I-NP	O
that	that	WDT	B-NP	O
was	be	VBD	B-VP	O
growing	grow	VBG	I-VP	O
Gram-negative	Gram-negative	JJ	B-NP	O
rods	rod	NNS	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
current	current	JJ	I-NP	O
report	report	NN	I-NP	O
is	be	VBZ	B-VP	O
that	that	IN	B-SBAR	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
growing	grow	VBG	I-VP	O
Serratia	Serratia	NNP	B-NP	O
marcescens	marcescen	NNS	I-NP	O
which	which	WDT	B-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
staph	staph	NN	B-NP	O
sensitive	sensitive	JJ	B-ADJP	O
to	to	TO	B-PP	O
ceftazidime	ceftazidime	NN	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
prescribed	prescribe	VBN	I-VP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
total	total	NN	I-NP	O
of	of	IN	B-PP	O
14	14	CD	B-NP	O
days	day	NNS	I-NP	O
.	.	.	O	O

FOLLOW	FOLLOW	NNP	B-NP	O
UP	UP	NNP	I-NP	O
:	:	:	O	O
She	She	NNP	B-NP	O
will	will	MD	B-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Antony	Antony	NNP	I-NP	O
Baldonado	Baldonado	NNP	I-NP	O
on	on	IN	B-PP	O
10/12/07	10/12/07	CD	B-NP	O
at	at	IN	B-PP	O
9	9	CD	B-NP	O
:	:	:	O	O
30	30	CD	B-NP	O
a.m.	a.m.	RB	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
has	have	VBZ	B-VP	O
an	an	DT	B-NP	O
appointment	appointment	NN	I-NP	O
scheduled	schedule	VBN	B-VP	O
.	.	.	O	O

TO	TO	TO	B-PP	O
DO	DO	NNP	B-NP	O
LIST	LIST	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
an	an	DT	B-NP	O
80	80	CD	I-NP	O
%	%	NN	I-NP	O
left	leave	VBD	B-VP	O
circumflex	circumflex	NN	B-NP	O
lesion	lesion	NN	I-NP	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
not	not	RB	I-VP	O
stented	stente	VBN	I-VP	O
.	.	.	O	O

This	This	DT	B-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
,	,	,	I-VP	O
___	___	VB	I-VP	O
28.20	28.20	CD	B-NP	O
__	__	NN	I-NP	O
,	,	,	O	O
whether	whether	IN	B-SBAR	O
she	she	PRP	B-NP	O
needs	need	VBZ	B-VP	O
a	a	DT	B-NP	O
second	second	JJ	I-NP	O
intervention	intervention	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
future	future	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
does	do	VBZ	B-VP	O
appear	appear	VB	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
asymptomatic	asymptomatic	JJ	B-ADJP	O
,	,	,	O	O
but	but	CC	O	O
she	she	PRP	B-NP	O
does	do	VBZ	B-VP	O
continue	continue	VB	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
the	the	DT	B-NP	O
deep	deep	JJ	I-NP	O
lateral	lateral	JJ	I-NP	O
T	T	NN	I-NP	O
wave	wave	NN	I-NP	O
inversion	inversion	NN	I-NP	O
suggesting	suggest	VBG	B-VP	O
the	the	DT	B-NP	O
areas	area	NNS	I-NP	O
of	of	IN	B-PP	O
abnormal	abnormal	JJ	B-NP	O
blood	blood	NN	I-NP	O
flow	flow	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
heart	heart	NN	I-NP	O
.	.	.	O	O

It	It	PRP	B-NP	O
was	be	VBD	B-VP	O
thought	think	VBN	I-VP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
RCA	RCA	NN	I-NP	O
lesion	lesion	NN	I-NP	O
was	be	VBD	B-VP	O
more	more	RBR	B-ADJP	O
likely	likely	JJ	I-ADJP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
the	the	DT	B-NP	O
cause	cause	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
inferior	inferior	JJ	I-NP	O
wall	wall	NN	I-NP	O
hypokinesis	hypokinesis	NN	I-NP	O
,	,	,	O	O
so	so	IN	O	O
that	that	DT	B-NP	O
was	be	VBD	B-VP	O
the	the	DT	B-NP	O
procedure	procedure	NN	I-NP	O
performed	perform	VBD	B-VP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
for	for	IN	B-PP	O
hospital-acquired	hospital-acquired	JJ	B-NP	O
pneumonia	pneumonia	NN	I-NP	O
with	with	IN	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
and	and	CC	I-NP	O
ceftazidime	ceftazidime	NN	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
will	will	MD	B-VP	O
continue	continue	VB	I-VP	O
until	until	IN	B-PP	O
1/16/07	1/16/07	CD	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
rash	rash	NN	I-NP	O
here	here	RB	B-ADVP	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
thought	think	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
Plavix	Plavix	NN	B-NP	O
related	relate	VBN	B-ADJP	O
.	.	.	O	O

If	If	IN	B-SBAR	O
the	the	DT	B-NP	O
rash	rash	NN	I-NP	O
resolves	resolve	VBZ	B-VP	O
on	on	IN	B-PP	O
ticlopidine	ticlopidine	NN	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
may	may	MD	B-VP	O
need	need	VB	I-VP	O
to	to	TO	I-VP	O
readdress	readdress	VB	I-VP	O
whether	whether	IN	B-SBAR	O
or	or	CC	O	O
not	not	RB	O	O
this	this	DT	B-NP	O
was	be	VBD	B-VP	O
actually	actually	RB	B-ADVP	O
due	due	JJ	B-ADJP	O
to	to	TO	B-PP	O
Plavix	Plavix	NNP	B-NP	O
.	.	.	O	O

It	It	PRP	B-NP	O
was	be	VBD	B-VP	O
recommended	recommend	VBN	I-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
follow	follow	VB	B-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
an	an	DT	B-NP	O
allergist	allergist	NN	I-NP	O
in	in	IN	B-PP	O
about	about	RB	B-NP	O
a	a	DT	I-NP	O
month	month	NN	I-NP	O
from	from	IN	B-PP	O
her	her	PRP$	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
who	who	WP	B-NP	O
can	can	MD	B-VP	O
review	review	VB	I-VP	O
the	the	DT	B-NP	O
records	record	NNS	I-NP	O
and	and	CC	O	O
determine	determine	VB	B-VP	O
whether	whether	IN	B-SBAR	O
she	she	PRP	B-NP	O
should	should	MD	B-VP	O
start	start	VB	I-VP	O
Plavix	Plavix	NNP	B-NP	O
or	or	CC	O	O
maintain	maintain	VB	B-VP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
ticlopidine	ticlopidine	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
platelets	platelet	NNS	I-NP	B-cell_type
should	should	MD	B-VP	O
be	be	VB	I-VP	O
monitored	monitor	VBN	I-VP	O
given	give	VBN	B-PP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
started	start	VBD	B-VP	O
on	on	IN	B-PP	O
ticlopidine	ticlopidine	NN	B-NP	O
and	and	CC	O	O
there	there	EX	B-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
risk	risk	NN	I-NP	O
of	of	IN	B-PP	O
TTP	TTP	NN	B-NP	B-protein
associated	associate	VBN	B-VP	O
with	with	IN	B-PP	O
this	this	DT	B-NP	O
medication	medication	NN	I-NP	O
.	.	.	O	O

eScription	eScription	NN	B-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
2-5081465	2-5081465	CD	B-NP	O
EMSSten	EMSSten	NNP	I-NP	O
Tel	Tel	NNP	I-NP	O
CC	CC	NNP	I-NP	O
:	:	:	O	O
Lenard	Lenard	NNP	B-NP	O
Prey	Prey	NNP	I-NP	O
M.D.	M.D.	NNP	I-NP	O
Nor	Nor	NNP	I-NP	O
Ties	Ties	NNP	I-NP	O
Pro	Pro	NNP	I-NP	O
Health	Health	NNP	I-NP	O
Care	Care	NNP	I-NP	O
Squite	Squite	NNP	I-NP	O
Kan	Kan	NNP	I-NP	O
Fallsaleri	Fallsaleri	NNP	I-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
AUGUSTYN	AUGUSTYN	NNP	B-NP	O
,	,	,	O	O
BURL	BURL	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
KITE	KITE	NNP	B-NP	O
,	,	,	O	O
JAMIE	JAMIE	NNP	B-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
3181966	3181966	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
10/3/07	10/3/07	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
10/29/07	10/29/07	CD	B-NP	O

